| Literature DB >> 29071223 |
Behzad Jafari1,2,3, Maryam Hamzeh-Mivehroud1,2, Ali Akbar Alizadeh1, Mehdi Sharifi1,2, Siavoush Dastmalchi1,2.
Abstract
Purpose: Receptor tyrosine kinase (RTK) inhibitors are widely used pharmaceuticals in cancer therapy. Fibroblast growth factor receptors (FGFRs) are members of RTK superfamily which are highly expressed on the surface of carcinoma associate fibroblasts (CAFs). The involvement of FGFRs in different types of cancer makes them promising target in cancer therapy and hence, the identification of novel FGFR inhibitors is of great interest. In the current study we aimed to develop an alignment independent three dimensional quantitative structure-activity relationship (3D-QSAR) model for a set of 26 FGFR2 kinase inhibitors allowing the prediction of activity and identification of important structural features for these inhibitors.Entities:
Keywords: 3D-QSAR; Docking; FGFR2; GRIND descriptors; Tyrosine kinase inhibitors
Year: 2017 PMID: 29071223 PMCID: PMC5651062 DOI: 10.15171/apb.2017.049
Source DB: PubMed Journal: Adv Pharm Bull ISSN: 2228-5881
Figure 1The most important structural variables in the 3D-QSAR model
|
|
|
|
|
|
|
| O-O | 10.8-11.2 | 85 | negative | about half of the compounds | NH of the amide in the ring or outside the ring and NH or its bioisoesters |
| O-N1 | 13.6-14 | 440 | negative | almost all of the compounds | amine of indole/ piperazine/ pyrrole piperidine/ pyridine/ quinolone and hydroxyl /amine of endmost moiety or NH between two heterocyclic ring or indole ring |
| O-N1 | 4.4-4.8 | 417 | negative | almost all of the compounds | amide carbonyl/ sulfonamide nitrogen and oh of endmost moiety/ NH of amide or NH in the indole ring |
| O-TIP | 19.2-19.6 | 512 | positive | one third of the compounds | NH in the ring or amide and endmost heterocyclic ring/methyl attached to the indole ring |
| DRY-TIP | 12.2-12.8 | 379 | positive | all of the compounds | indole/quinolone ring (or bioisoesters) and halide/alkyl in the end most moiety |
| N1-N1 | 16-16.4 | 156 | negative | one third of the compounds | nitrogen of the heterocyclic compounds (piperazine and indole ring) and nitrogen of amide |
Figure 2Statistics for the PLS model for FGFR2 inhibitors
|
|
|
|
|
|
|
|
|
|
|
| 1 | 10.55 | 10.55 | 0.21 | 0.38 | 0.87 | 0.87 | 0.59 | 0.55 | 0.49 |
| 2 | 10.76 | 21.31 | 0.15 | 0.29 | 0.06 | 0.93 | 0.75 | 0.71 | 0.65 |
| 3 | 10.16 | 31.47 | 0.11 | 0.29 | 0.03 | 0.96 | 0.76 | 0.75 | 0.67 |
Observed vs predicted inhibitory activities for FGFR2 inhibitors used in this work
|
|
|
|
|
|
|
| 1 | 5.7 | 5.77 | 14 | 6.6 | 6.48 |
| 2 | 7 | 7.06 | 15 | 6.7 | 6.85 |
| 3 | 7 | 7.04 | 16a | 7.5 | 6.79 |
| 4 | 7.5 | 7.65 | 17 | 5.3 | 5.41 |
| 5 | 5.8 | 5.87 | 18 | 5.5 | 5.48 |
| 6 | 6.4 | 6.37 | 19a | 6.7 | 6.63 |
| 7a | 6.3 | 6.53 | 20 | 5.6 | 5.65 |
| 8 | 6.1 | 6.03 | 21 | 7 | 6.82 |
| 9a | 5.4 | 5.95 | 22 | 6.1 | 6.00 |
| 10 | 6.1 | 5.95 | 23 | 6.2 | 6.13 |
| 11 | 6.2 | 6.29 | 24 | 7.1 | 6.92 |
| 12 | 5.6 | 5.82 | 25 | 6.2 | 6.20 |
| 13a | 5.8 | 5.59 | 26 | 6 | 5.91 |
aTest set compounds.
Figure 3